0000899243-15-007336.txt : 20151030 0000899243-15-007336.hdr.sgml : 20151030 20151030161524 ACCESSION NUMBER: 0000899243-15-007336 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151028 FILED AS OF DATE: 20151030 DATE AS OF CHANGE: 20151030 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 28TH STREET STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 2525 28TH STREET STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rolfe Lindsey CENTRAL INDEX KEY: 0001650504 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 151187679 MAIL ADDRESS: STREET 1: C/O CLOVIS ONCOLOGY, INC. STREET 2: 499 ILLINOIS STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-10-28 0 0001466301 Clovis Oncology, Inc. CLVS 0001650504 Rolfe Lindsey C/O CLOVIS ONCOLOGY, INC. 2525 28TH STREET, SUITE 100 BOULDER CO 80301 0 1 0 0 See Remarks Common Stock 2015-10-28 4 M 0 4000 3.08 A 4000 D Common Stock 2015-10-28 4 S 0 500 95.779 D 3500 D Common Stock 2015-10-28 4 S 0 1300 97.313 D 2200 D Common Stock 2015-10-28 4 S 0 1962 98.906 D 238 D Common Stock 2015-10-28 4 S 0 238 99.218 D 0 D Employee stock option (right to buy) 3.08 2015-10-28 4 M 0 4000 0.00 D 2020-04-07 Common Stock 4000 23034 D This transaction was executed in multiple trades at prices ranging from $95.365 to $96.300 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $97.000 to $97.920 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $98.120 to $99.120 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $99.150 to $99.290 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2015. The option vested as to 25% of the shares on April 1, 2011, and the remainder vested in substantially equal installments over the 36 months immediately following such date. Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance /s/ Lindsey Rolfe 2015-10-30